FDA Approves Tecentriq as First ctDNA-Guided Bladder Cancer Therapy 18 May 2026·852 words·5 mins FDA Roche Tecentriq Bladder Cancer CtDNA Precision Oncology Cancer Immunotherapy Natera
New Drug Candidate STF-1623 Activates Innate Immunity in Solid Tumors 5 September 2025·594 words·3 mins Cancer Immunotherapy Innate Immunity STF-1623 ENPP1 Solid Tumors Stanford Lingyin Li
